A Promising New Era in Cancer Treatment
One of the most exciting advances in cancer research is an innovative approach that involves removing a patient’s immune cells, modifying those cells to identify cancer, then infusing those cells in the patient to fight cancer. We have long believed in the promise of modifying T cells to treat certain blood cancers and our singular focus is developing cell therapy.
We are developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Our dual platform has the potential to change the paradigm of cancer therapy and address both hematological and solid tumor cancers.
We have one of the leading pipelines in cell therapy within the industry. Our pipeline currently includes investigational therapies and next generation technologies for a range of hematologic malignancies and solid tumors.
We are currently investigating multiple indications in the axicabtagene ciloleucel and the KTE-C19 development program as well as for our TCR pipeline and second generation technology. Our areas of research include a variety of blood cancers and solid tumors.
Expanded access programs allows for potential access to investigational therapies in certain rare circumstances for patients who unable to participate in an ongoing clinical trial or whose treatment options are otherwise limited. For more information regarding Kite’s expanded access policy, please click on the link below.